Navidea Biopharmaceuticals Inc.
NAVB
NAVB was delisted on the 5th of October, 2023.
56 hedge funds and large institutions have $5.76M invested in Navidea Biopharmaceuticals Inc. in 2017 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 13 increasing their positions, 13 reducing their positions, and 0 closing their positions.
26% more call options, than puts
Call options by funds: $24K | Put options by funds: $19K
8% more funds holding
Funds holding: 52 → 56 (+4)
0% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 13
23% less capital invested
Capital invested by funds: $7.5M → $5.76M (-$1.74M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$93.4K |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$33.6K |
| 3 |
Wells Fargo
San Francisco,
California
|
+$23.9K |
| 4 |
Jane Street
New York
|
+$19.9K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$18.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SFS
Sowell Financial Services
North Little Rock,
Arkansas
|
-$347K |
| 2 |
SIM
Spark Investment Management
New York
|
-$105K |
| 3 |
Millennium Management
New York
|
-$104K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$18.4K |
| 5 |
Goldman Sachs
New York
|
-$15.5K |
NAVB Hedge Fund Activity: Q3 2017 in Review
56 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Navidea Biopharmaceuticals Inc. (NAVB) for Q3 2017, worth a combined $5.76M — down 23% from $7.5M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new NAVB positions and 0 closed out — a net gain of 5 holders — while 13 added to existing stakes and 13 trimmed.
The largest buyer was UBS Group, adding an estimated $93.4K. The largest seller was Sowell Financial Services, cutting an estimated $347K.
- 56 institutional investors held Navidea Biopharmaceuticals Inc. (NAVB) as of Q3 2017, up from 52 in Q2 2017.
- Funds reported $5.76M of Navidea Biopharmaceuticals Inc. stock for Q3 2017, down 23% quarter-over-quarter.
- 5 funds opened new Navidea Biopharmaceuticals Inc. positions in Q3 2017 and 0 closed out, a net change of +5 holders.
- The largest Navidea Biopharmaceuticals Inc. buyer in Q3 2017 was UBS Group, an estimated $93.4K added.
- The largest Navidea Biopharmaceuticals Inc. seller in Q3 2017 was Sowell Financial Services, an estimated $347K sold.
Based on aggregated 13F filings for Q3 2017.